Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
PRO1184 1X9HDTV Distribution Amplifier
PRO1184 for Cancer Clinical Trial 2024 | Power
PRO1184 for Mesothelioma Clinical Trial 2023 | Power
First Patient Dosed with PRO1184 and PRO1160 Cleared for Study ...
Rinatabart Sesutecan | PRO1184 | Rina-S » ADC Review
Corinthian Prostars MANCHESTER UTD Home STAPLETON PRO1184 Loose With ...
The High Hydrophilicity of ADC Linker Has Become the Main Trend in ...
中国Biotech公司ADC产品技术特色 2021年8月， 荣昌生物 就维迪西妥单抗与 Seagen 达成潜在总额高达26亿美元的授权交易 ...
普方生物两款ADC喜获新进展|PRO1184人体临床试验启动给药，PRO1160获FDA批准启动I期临床 - 知乎
A phase I/II study of azacitidine in combination with temozolomide in ...
Abstract 6880: Rinatabart sesutecan (PRO1184) in combination with ...
普方生物两款ADC喜获新进展｜PRO1184人体临床试验启动给药，PRO1160获FDA批准启动I期临床_腾讯新闻
18亿美元被收购！扒扒普方生物的管线和平台医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
普方生物：FRα ADC临床申请获受理 Armstrong 2022年11月18日，普方生物PRO184 注射液的临床试验申请获得NMPA受理 ...
ProfoundBio showcases PRO1184's antitumor activity at AACR 2023
Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed ...
Abstract 1085: PRO1184, a novel folate receptor alpha-directed antibody ...
Abstract 2637: Novel folate receptor alpha-directed antibody-drug ...
普方生物宣布以FRα为靶点的ADC药物PRO1184已完成首例受试者给药医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
ADC Linker高亲水性成为主要改造趋势 追溯 普方生物成立于2018年，始创于美国华盛顿州西雅图。三位核心创始人分别是Baiteng ...
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid ...
Introduction to ADC Drug Payloads – AntBio
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO ...
临床进展丨普方生物：ADC药物PRO1184获得FDA临床许可医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate ...
普方生物宣布以FRα为靶点的ADC药物PRO1184已完成首例受试者给药-美通社PR-Newswire
Antibody-drug Conjugate Information | ADCdb
FOLR1 （叶酸受体α）靶点布局加速，驱动多维肿瘤治疗新浪潮-公司新闻-吉满生物科技(上海)有限公司
FOLR1（叶酸受体α）靶点布局加速，驱动多维肿瘤治疗新浪潮 - 知乎
What Are ADC Linkers: Reviewing Antibody–Drug Conjugates
卵巢癌中的ADC临床疗效汇总(2026.4) - 知乎
Rinatabart sesutecan（PRO1184）联合标准治疗在卵巢癌模型中显示出协同作用 - 知乎
普方生物FRα ADC申报临床 11月18日，普方生物递交注射用PRO1184的临床试验获得CDE受理。PRO1184是一种ADC药物，通过 ...
FRα靶向治疗：癌症临床实践的革命者与挑战者 - 知乎
【AACR 2023】ADC药物”角力”AACR-自主发布-资讯-生物在线
In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various ...
百拓众创丨普方生物FRα靶向ADC获FDA快速通道资格医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Severing Ties: Quantifying the Payload Release from Antibody Drug ...
MCL1 inhibitor PRT1419 Demonstrates Antitumor Activity in PBRM1-altered ...
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based ...
FRα表达卵巢癌新药！FDA授予Rina-S快速通道资格认定 - 知乎
EGFR突变肺癌、子宫内膜癌新药临床试验：ADC新药注射用PRO1184-印塔健康官网
AACR 2023 Poster 6775: Indivumed Services - Combination of Spatial ...
AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR ...
18亿美元ProfoundBio被收购，改善Exatecan疏水性是关键 - Chemexpress
PRO1184-10 1/8 Trencher X MT 3.8" M2 MX38 Raid Mounted Tires (2 ...
普方生物宣布ADC药物PRO1184获得美国FDA的临床试验许可并任命Naomi Hunder博士为公司的首席医学官 - 知乎
普方生物又一款ADC药物在华申报临床 12月8日，据CDE官网显示，普方生物提交注射用PRO1107的临床申请获得受理。在此之前，2月16日 ...
辉瑞、杨森、复宏汉霖、普方生物等公司1类新药获批临床|复宏汉霖|适应症|注射液_新浪新闻
FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing ...
Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer
a) The AS1411-prodrug conjugate self-assembled micelles encapsulating ...
ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation ...
ADC领域极具潜力的抗癌靶点—FRα - 知乎
Updated ESMO Clinical Practice Guideline on Renal Cell Carcinoma - ESMO ...
ProLine PRO1184-25 - ProLine Trencher 3.8 Tyres Mounted on Grey F-11 ...
2126803-41-4，RIP2 Kinase Inhibitor 4，PROTAC(蛋白降解靶向嵌合体)-UDP糖丨MOF丨金属有机框架丨 ...
普方生物FRα靶向ADC新药rinatabart sesutecan获FDA快速通道资格，针对卵巢癌
卵巢癌新药（Rina-S），获“突破疗法”认定，ORR达55.6%！ - 知乎
(a) Rational design of multifunctional prodrug conjugates composed of ...
FDA Grants FTD to Rinatabart Sesutecan for FRα-Expressing Ovarian ...
Rina-S (rinatabart sesutecan) / Genmab
Pro-Line Trencher X 3.8" All Terrain Mounted Tires (2) PRO1184-13 ...
超7倍回报！ADC公司普方生物被Genmab以18亿美元全现金收购
Pro-Line Trencher X 3.8" Tire 1/2" Offset (2) (Black) [PRO1184-11-P ...
Structure of antibody–drug conjugates that have reach clinical trials ...
The Landscape of Antibody-drug Conjugate (ADC): Production, Mechanisms ...
分子骨架跃迁工具3DLinker 评测-CSDN博客
FDA Grants FTD to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer
普方生物：在第38届癌症免疫治疗学会（SITC 2023）年会发表ADC管线数据_新浪财经_新浪网
Genmab/普方生物：FRα ADC启动三期临床 Armstrong 2024年10月1日， Genmab 在Clinicaltrials ...
已投企业 | 普方生物完成7000万美元的A+轮融资，推进新型抗体偶联药物的临床开发医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
General structure of antibody drug conjugates (ADC) and targeted ...
Pro-Line Trencher X 3.8" Tire w/F-11 17mm 1/2" Offset MT Wheel (2 ...
创始人出自Seagen班底，斩获近2.5亿美元融资，看国产ADC biotech如何走出全球化姿态 在即将到来的2024 AACR会议上，已有 ...
Bioninja Antibodies at Liam Threlfall blog
Structural components of Antibody drug conjugates and their functional ...
有效载荷（payload）的多样性：ADC药物未来开发的关键一环 - 脉脉
AACR年会丨普方生物添新将，Zhu Chen博士出任首席科学官 2022年3月10日/医麦客新闻 eMedClub News/--近日 ...
Prodrug activation by membrane-anchored enzymes. High densities of ...
Rinatabart Sesutecan Receives FDA Fast Track Designation for Patients ...
Structural elucidation of antibody drug conjugates (ADCs) using the IgG ...
),%20HER2-negative%20Breast%20Cancer,%20Hormone%20Receptor-positive%20Breast%20Cancer:%0A%0APRO1184%20for%20Mesothelioma.png?md=1)
